Benefits of VILPA in Young Adults

Health Behavior Clinical Trial

Official title:

Benefits of Wearable Acceleration-Monitored Simulated Vigorous Intermittent Lifestyle Physical Activity (VILPA) in Young Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06259370
• Other study ID #: K001
• Status: Completed
• Phase: N/A
• Start date: May 12, 2023
• Est. completion date: December 31, 2023

Study information

• Verified date: February 2024
• Source: Sun Yat-sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinicaltrial is to assess and compare isokinetic performance, surface electromyography, laboratory parameters, and cardiorespiratory function both before and after engaging in vigorous intermittent lifestyle physical activity(VILPA) within a healthy population.

The main question it aims to answer is:

[1] Does VILPA yield effective outcomes? Throughout the course of the trial, participants will engage in a simulated regimen of vigorous intermittent lifestyle physical activity for a duration of 8 weeks. The efficacy of the exercise protocol will be quantified and evaluated through the utilization of a wearable device.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 31, 2023
• Est. primary completion date: July 10, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Healthy Adults

• No exercise habits (more than 3 months)

Exclusion Criteria:

• Exercising = 3 times per week;

• the presence of chronic diseases, such as hypertension, hyperglycemic states, etc;

• have conducted an exercise program in the past three months.

Related Conditions & MeSH terms

• Activity, Motor
• Health Behavior

Intervention

Behavioral:
• Vigorous intermittent lifestyle physical activity
The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.

Locations

Country	Name	City	State
China	Guangdong Pharmaceutical University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Xiao-dong Zhuang

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Isokinetic strength testing	Isokinetic strength testing with the Isomed 2000	30 minutes
Primary	Surface electromyography	a standard surface electromyography system (MyoMove-EOW, NCC, China) was utilized. Surface electrodes were placed using the belly tendon method at 6 specified locations on both sides of the lower legs (anterior tibialis on both sides, gastrocnemius on both sides, and soleus on both sides). The electrode placement positions and operational procedures strictly adhered to the SENIAM guidelines (http://www.seniam.org). During the testing process, root mean square (RMS) and averaged electromyography (AEMG) values were collected to reflect the muscle force and motor unit recruitment of the selected muscle groups.	15 minutes
Secondary	Blood lipid	encompassing high-density lipoprotein cholesterol (HDL-C) and triglycerides, were assessed using the CardioChek device (Polymer Technology Systems, Inc., 7736 Zionsville Road, USA)	5 minutes